# ScoreItem: Glicose Urin√°ria

**ID:** `c77cedd3-2800-7b7d-8b5e-03585a2f62eb`
**FullName:** Glicose Urin√°ria (Exames - Laboratoriais)
**Unit:** mg/dL

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 9 artigos
- Avg Similarity: 0.566

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-7b7d-8b5e-03585a2f62eb`.**

```json
{
  "score_item_id": "c77cedd3-2800-7b7d-8b5e-03585a2f62eb",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Glicose Urin√°ria (Exames - Laboratoriais)
**Unidade:** mg/dL

**30 chunks de 9 artigos (avg similarity: 0.566)**

### Chunk 1/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** results | **Similarity:** 0.621

e plasma sodium levels in patients with the syndrome of inappropriate anti-diuresis. J Am Soc Nephrol. 2020;31:615¬ñ24. 
32. Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Mon-nerat S, Bathelt C, Vogt DR, Berres M, Winzeler B, Bridenbaugh SA, Christ-Crain M. Treatment eÔ¨Äect of the SGLT2 inhibitor empagliÔ¨Çozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crosso-ver trial. J Am Soc Nephrol. 2023;34:322¬ñ32. 
33. Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, Hare MJL, Calder GL, Epa DS, George EM, Giri R, Kotowicz MA, Kyi M, Lafontaine N, MacIsaac RJ, Nolan BJ, O¬íNeal DN, Renouf D, Varadarajan S, Wong J, Xu S, Bach LA. SGLT2 inhibi-tors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019;104:3077¬ñ87. 
34. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czer-wiec FS, Orlandi C, SALT Investigators.

---

### Chunk 2/30
**Article:** Resist√™ncia Insul√≠nica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.614

g/dL, HbA1c <5,7%.
- Pr√©-diabetes: jejum ‚â•100 e <126 mg/dL; 2h OGTT ‚â•140 e <200 mg/dL; HbA1c ‚â•5,7 e <6,5%; qualquer positividade confirma.
- Diabetes: jejum ‚â•126 mg/dL; 2h OGTT ‚â•200 mg/dL; glicemia aleat√≥ria ‚â•200 mg/dL com sintomas t√≠picos; HbA1c ‚â•6,5%.
- Repetir exames na aus√™ncia de correla√ß√£o cl√≠nica/sintomas antes de confirmar diagn√≥stico.
## S√≠ndrome Metab√≥lica: Defini√ß√£o e Crit√©rios
- Evolu√ß√£o da RI para s√≠ndrome metab√≥lica: hipertens√£o, DM2, risco cardiovascular (AVC/infarto).
- Defini√ß√£o pr√°tica: insufici√™ncia do tecido adiposo para lidar com supernutri√ß√£o.
- Crit√©rios (ATP III/IDF): circunfer√™ncia abdominal elevada (cortes vari√°veis por etnia), TG >150 mg/dL, HDL baixo, PA elevada, glicemia alterada; tratamento medicamentoso conta ponto.
- Condi√ß√µes associadas: SOP, lipodistrofias, hist√≥ria familiar, obesidade visceral.

---

### Chunk 3/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.598

inJapan.OpenForumInfectDis.2018;5:ofy216.381.YangCJ,ChenDP,WenYH,etal.Evaluationthediagnosticaccuracyof
albuminuriadetectioninsemi-quantitativeurinalysis.ClinChimActa.2020;510:177‚Äì180.382.KouriT,NokelainenP,PelkonenV,etal.EvaluationoftheARKRAYAUTIONElevenreectometerindetectingmicroalbuminuriawithAUTIONScreenteststripsandproteinuriawithAUTIONSticks10PAstrips.ScandJClinLabInvest.2008;69:52‚Äì64.383.NagrebetskyA,JinJ,StevensR,etal.Diagnosticaccuracyofurinedipsticktestinginscreeningformicroalbuminuriaintype2diabetes:acohortstudyinprimarycare.FamPract.2012;30:142‚Äì152.384.NahEH,ChoS,KimS,etal.Comparisonofurinealbumin-to-creatinineratio(ACR)betweenACRstriptestandquantitativetestinprediabetesanddiabetes.AnnLabMed.2016;37:28‚Äì33.385.ShinJI,ChangAR,GramsME,etal.Albuminuriatestinginhypertensionanddiabetes:anindividual-participantdatameta-analysisinaGlobalConsortium.Hypertension.2021;78:1042‚Äì1052.386.PantaloneKM,JiX,KongSX,etal.Unmetneedsandopportunitiesforoptimalmanagementofpatientswithty

---

### Chunk 4/30
**Article:** Carboidratos IV (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.597

ente 1 (Homem, 42 anos):**
    *   Curva Glic√™mica e Insulin√™mica:
        *   Basal: Glicose 89 mg/dL, Insulina 13 ¬µU/mL
        *   30 min: Insulina elevada (valor exato n√£o mencionado)
        *   60 min: Insulina muito elevada ("absurdo")
        *   120 min: Glicose 94 mg/dL, Insulina 81 ¬µU/mL
*   **Paciente 2 (Mulher, 71 anos):**
    *   Curva Glic√™mica e Insulin√™mica:
        *   Basal (Jejum): Glicose 90 mg/dL, Insulina 10 ¬µU/mL
        *   30 min: Glicose 152 mg/dL, Insulina 51 ¬µU/mL
        *   60 min: Insulina 209 ¬µU/mL
        *   120 min: Glicose 48 mg/dL (hipoglicemia de rebote), Insulina 110 ¬µU/mL
        *   180 min: Glicose 80 ¬µU/mL
    *   Tomografia Computadorizada com Escore de C√°lcio Coronariano:
        *   Pontua√ß√£o total: 582
        *   Percentil: 97 para idade e sexo
        *   Risco cardiovascular em 10 anos (calculado pela tabela MESA): 10,7%
*   **An√°lise sobre Ado√ßantes (Conte√∫do Educacional):**
    *   **Aspartame:** Associado em estudo

---

### Chunk 5/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.591

albumindeterminationinpatientswithtype1diabetes.BrazJMedBiolRes.2002;35:337‚Äì343.347.KimY,ParkS,KimMH,etal.Canasemi-quantitativemethodreplacethe
currentquantitativemethodfortheannualscreeningofmicroalbuminuriainpatientswithdiabetes?Diagnosticaccuracyandcost-savinganalysisconsideringthepotentialhealthburden.PLoSOne.2020;15:e0227694.348.LeFlochJP,MarreM,RodierM,etal.InterestofClinitekMicroalbumininscreeningformicroalbuminuria:resultsofamulticentrestudyin302diabeticpatients.DiabetesMetab.2001;27:36‚Äì39.349.LeongSO,LuiKF,NgWY,etal.Theuseofsemi-quantitativeurinetest-
strip(MicralTest)formicroalbuminuriascreeninginpatientswithdiabetesmellitus.SingaporeMedJ.1998;39:101‚Äì103.350.LimD,LeeDY,ChoSH,etal.Diagnosticaccuracyofurinedipstickforproteinuriainolderoutpatients.KidneyResClinPract.2014;33:199‚Äì203.351.LimS,YuHJ,LeeS,etal.EvaluationoftheURiSCAN2ACRStripto
estimatetheurinealbumin/creatinineratios.JClinLabAnal.2017;32:e22289.352.LinCJ,ChenHH,PanCF,etal.Thecharacteristicsofnewsemi-
quantit

---

### Chunk 6/30
**Article:** Resist√™ncia Insul√≠nica (2024)
**Journal:** Pos Graduacao MFI
**Section:** introduction | **Similarity:** 0.589

star por etnia; japoneses possuem cortes distintos).
- Rela√ß√£o cintura-quadril: √∫til em alguns contextos.
- Ind√≠cios cut√¢neos: acantose nigricans e acroc√≥rdons; circunfer√™ncia do pesco√ßo aumentada tamb√©m sugere risco.
## Diagn√≥stico Laboratorial e Avalia√ß√£o Precoce
- OGTT: curva 0/30/60/90/120 minutos; glicemia 2h ‚â•200 mg/dL confirma DM; co-dosagem de insulina ajuda a inferir RI.
- HOMA-IR e QUICKI como √≠ndices estimativos; insulina de jejum pode sinalizar RI precocemente.
- TG/HDL < 3 sugerido como indicador √∫til; glicemia de jejum e HbA1c s√£o marcadores mais tardios de altera√ß√£o glic√™mica.
- Clamp euglic√™mico hiperinsulin√™mico √© padr√£o-ouro em pesquisa.
## Crit√©rios Diagn√≥sticos: Normalidade, Pr√©-Diabetes e Diabetes
- Normal: glicemia <100 mg/dL, OGTT 2h <140 mg/dL, HbA1c <5,7%.
- Pr√©-diabetes: jejum ‚â•100 e <126 mg/dL; 2h OGTT ‚â•140 e <200 mg/dL; HbA1c ‚â•5,7 e <6,5%; qualquer positividade confirma.

---

### Chunk 7/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.589

tNZJMed.1992;22:334‚Äì337.338.GilbertRE,AkdenizA,JerumsG.Detectionofmicroalbuminuriaindiabeticpatientsbyurinarydipstick.DiabetesResClinPract.1997;35:57‚Äì60.339.GrazianiMS,GambaroG,MantovaniL,etal.Diagnosticaccuracyofa
reagentstripforassessingurinaryalbuminexcretioninthegeneralpopulation.NephrolDialTransplant.2008;24:1490‚Äì1494.340.GuyM,NewallR,BorzomatoJ,etal.Useofarst-lineurineprotein-to-creatinineratiostriptestonrandomurinestoruleoutproteinuriain
patientswithchronickidneydisease.NephrolDialTransplant.2008;24:1189‚Äì1193.341.GuyM,NewallR,BorzomatoJ,etal.Diagnosticaccuracyoftheurinary
albumin:creatinineratiodeterminedbytheCLINITEKMicroalbuminandDCA2000√æfortherule-outofalbuminuriainchronickidneydisease.ClinChimActa.2008;399:54‚Äì58.342.HasslacherC,MullerP,SchlipfenbacherRL.ResultsofamulticentrestudyforthedeterminationofmicroalbuminuriawithMicral-Test.KlinischesLabor.1995;41:441‚Äì447.343.HodelNC,HamadA,ReitherK,etal.Comparisonoftwodifferent
semiquantitativeurinarydipsticktestswithal

---

### Chunk 8/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.585

88‚Äì1801.512.StaplinN,RoddickAJ,EmbersonJ,etal.Neteffectsofsodium-glucoseco-
transporter-2inhibitionindifferentpatientgroups:ameta-analysisoflargeplacebo-controlledrandomizedtrials.EClinicalMedicine.2021;41:101163.513.HeerspinkHJL,StefanssonBV,Correa-RotterR,etal.Dapagliozininpatientswithchronickidneydisease.NEnglJMed.2020;383:1436‚Äì1446.514.PerkovicV,JardineMJ,NealB,etal.Canagliozinandrenaloutcomesintype2diabetesandnephropathy.NEnglJMed.2019;380:2295‚Äì2306.515.FerreiraJP,InzucchiSE,MattheusM,etal.Empagliozinanduricacidmetabolismindiabetes:aposthocanalysisoftheEMPA-REGOUTCOMEtrial.DiabetesObesMetab.2022;24:135‚Äì141.516.EMPA-KIDNEYCollaborativeGroup.Design,recruitment,andbaselinecharacteristicsoftheEMPA-KIDNEYtrial.NephrolDialTransplant.2022;37:1317‚Äì1329.517.NeuenBL,OshimaM,AgarwalR,etal.Sodium-glucosecotransporter2
inhibitorsandriskofhyperkalemiainpeoplewithtype2diabetes:a
meta-analysisofindividualparticipantdatafromrandomized,controlledtrials.Circulation.2022;145:1460‚Äì1470.

---

### Chunk 9/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.584

g.ClinNephrol.1999;51:220‚Äì227.366.ParsonsMP,NewmanDJ,NewallRG,etal.Validationofapoint-of-care
assayfortheurinaryalbumin:creatinineratio.ClinChem.1999;45:414‚Äì417.367.PendersJ,FiersT,DelangheJR.Quantitativeevaluationofurinalysistest
strips.ClinChem.2002;48:2236‚Äì2241.368.PoulsenPL,MogensenCE.Clinicalevaluationofatestforimmediateand
quantitativedeterminationofurinaryalbumin-to-creatinineratio.Abrief
report.DiabetesCare.1998;21:97‚Äì98.369.PugiaMJ,LottJA,KajimaJ,etal.Screeningschoolchildrenfor
albuminuria,proteinuriaandoccultbloodwithdipsticks.ClinChemLabMed.1999;37:149‚Äì157.370.SakaiN,FuchigamiH,IshizukaT,etal.Relationshipbetweena
urineprotein-to-creatinineratioof150mg/gramcreatinineanddipstickgradeinthehealthcheckup:substantialnumberoffalse-
negativeresultsforchronickidneydisease.TokaiJExpClinMed.2019;44:118‚Äì123.371.SalinasM,L√≥pez-Garrig√≥sM,FloresE,etal.Urinaryalbuminstripassay
asascreeningtesttoreplacequantitativetechnologyincertain
conditions.ClinChemLabMed.2018;57:204‚Äì209.

---

### Chunk 10/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.565

pagliozinandPreventionofAdverseOutcomesinChronicKidneyDisease;NA,notapplicable.
www.kidney-international.orgchapter3KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314S217

RationaleLargetrialsindividuallyandwhencombinedinmeta-analysisdemonstrateclearnetbenetsofSGLT2i,withnetbenetsparticularlylargeinpeoplewithoutdiabetesduetoalmostno
riskofseriousharmfromketoacidosisorlower-limbampu-
tation.Recommendation3.7.3:WesuggesttreatingadultswitheGFR20to45ml/minper1.73m2withurineACR<200mg/g(<20mg/mmol)withanSGLT2i(2B).Thisrecommendationplaceshighvalueonthepotentialforlong-termuseofSGLT2iinpeoplewithoutdiabeteswhohaveasub-
stantiallydecreasedGFRtoreducetheriskofkidneyfailurebut
recognizesremaininguncertaintyinthispopulationduetotheshortfollow-upintheRCTs.ItalsoplacesmoderatevalueonthebenetsofSGLT2ionriskofAKI,cardiovasculardeathandmyocardialinfarction,andriskofhospitalizationfromanycause.

---

### Chunk 11/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XI (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.565

evidenciada por uma insulina de jejum de 14,4 ¬µU/mL (o ideal seria abaixo de 6 ¬µU/mL) e picos de insulina p√≥s-refei√ß√£o que chegaram a 378 ¬µU/mL.**
- Mesmo ap√≥s 8 horas de jejum, a insulina do paciente n√£o baixou, indicando um problema metab√≥lico que n√£o seria detectado apenas pela glicemia.
- Um teste de curva glic√™mica, ap√≥s a ingest√£o de 75g de glicose, mostrou uma resposta anormal, com a glicose atingindo 169 mg/dL em 60 minutos e permanecendo elevada em 161 mg/dL ap√≥s duas horas.
- Os picos de insulina p√≥s-refei√ß√£o (134, 307 e 378 ¬µU/mL) excederam em muito os limites que indicam resist√™ncia insul√≠nica, como 50 ¬µU/mL ap√≥s duas horas ou 80 ¬µU/mL em qualquer momento.

---

### Chunk 12/30
**Article:** Carboidratos IV (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.564

a faixa de refer√™ncia, j√° indicam um problema.
*   **Hipoglicemia de Rebote (ou Reativa)**
    - Em pessoas com resist√™ncia √† insulina, o p√¢ncreas libera uma quantidade desproporcional de insulina, que, ap√≥s baixar a glicose, continua alta e causa uma queda excessiva (hipoglicemia).
    - Essa hipoglicemia gera um desejo desesperado por comida, criando um ciclo vicioso de picos de glicose e insulina.
### 3. An√°lise de Casos Cl√≠nicos e Risco Cardiovascular
*   **Caso 1: Homem, 42 anos**
    - Paciente com 101 kg, IMC de 32. Glicemia de jejum de 89, mas insulina basal de 13.
    - A curva insulin√™mica mostrou picos absurdos de insulina (ex: 81 em 60 minutos), confirmando a resist√™ncia √† insulina severa.
*   **Caso 2: Mulher, 71 anos**
    - Paciente com 87 kg, m√∫ltiplas queixas (dores, depress√£o, hipertens√£o). Glicemia de jejum de 90 e insulina de 10.

---

### Chunk 13/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.562

in,empagliozin,ertugliozin,ipragliozin,luseogliozin,remogliozin,sotagliozin,tofogliozin)ComparatorActivecomparator(e.g.,anotherglucose-loweringagent),placebo,orusualcareOutcomesCriticaloutcomes:kidneyfailure(includingCKDprogression)andall-causehospitalizationsOtheroutcomes:mortality,changeineGFR(includingacutechanges),complicationsofCKD,andadverseeventsStudydesignRandomizedcontrolledtrials(RCTs)ExistingsystematicreviewdataincludedKidneyDisease:ImprovingGlobalOutcomesDiabetesWorkGroup.KDIGO2022ClinicalPracticeGuidelineforDiabetes
ManagementinChronicKidneyDisease.KidneyInt.2022;102(5S):S1‚ÄìS127.23NufeldDepartmentofPopulationHealthRenalStudiesGroup,SGLTInhibitorMeta-AnalysisCardio-RenalTrialists‚ÄôConsortium.Impactofdiabetesontheeffectsofsodiumglucoseco-transporter-2inhibitorsonkidneyoutcomes:
collaborativemeta-analysisoflargeplacebo-controlledtrials.Lancet2022;400:1788‚Äì1801.511SoFtablesSupplementaryTableS10SearchdateNDPH2022:September2022;KDIGO2022:December2021;Updated:April20

---

### Chunk 14/30
**Article:** Dieta Cetog√™nica - Parte I (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.559

sa magra.
**Operacionaliza√ß√£o e fisiologia: hidrata√ß√£o, eletr√≥litos, glicose, glicog√™nio e m√©tricas (GKI) reduzem sintomas iniciais e orientam terapia.**
- Fase inicial: mobiliza√ß√£o de ~500 g de glicog√™nio (100 g f√≠gado, 400 g m√∫sculo) libera ~1 kg de √°gua (2 g √°gua por 1 g glicog√™nio), explicando ‚Äúperda de √°gua‚Äù na primeira semana.
- Hidrata√ß√£o/eletr√≥litos: ~2 litros de l√≠quidos/dia; 1 colher de ch√° de sal seguida de √°gua melhora sintomas em ~15 minutos; considerar sensibilidade ao sal (10%‚Äì20% dos hipertensos podem piorar).
- Glicemia: dieta normal 80‚Äì120 mg/dL; cetog√™nica 65‚Äì80 mg/dL; jejum em gestantes ~60 mg/dL; <70 mg/dL pode ser perigoso com insulina; extremos incluem 600 mg/dL em DT1 sem insulina e >300 mg/dL na cetoacidose; em jejum prolongado, 30 mg/dL pode ser tolerado quando h√° cetonas.

---

### Chunk 15/30
**Article:** Automated urine sediment analyzers underestimate the severity of hematuria in glomerular diseases (2021)
**Journal:** Scientific Reports
**Section:** other | **Similarity:** 0.559

¬ñ308 (2018). 34. Mashitani, T. et al. Association between dipstick hematuria and decline in estimated glomerular ltration rate among Japanese patients with type 2 diabetes: A prospective cohort study (diabetes distress and care registry at Tenri (DDCRT 14)). J. Diabetes Complicat. 31, 1079¬ñ1084 (2017). 35. Cho, E. J. et al. e ecient workow to decrease the manual microscopic examination of urine sediment using on-screen review of images. Clin. Biochem. 56, 70¬ñ74 (2018). 36. Lam, M. H. False ¬ëhematuria¬í due to bacteriuria. Arch. Pathol. Lab. Med. 119, 717¬ñ721 (1995). 37. Matsuo, C. et al. Inuence of commercial so drinks or green tea intake to occult blood and sugar tests with urinalysis reagent strips. Rinsho Byori 57, 834¬ñ841 (2009).Author contributionsW.S.Y.

---

### Chunk 16/30
**Article:** Automated urine sediment analyzers underestimate the severity of hematuria in glomerular diseases (2021)
**Journal:** Scientific Reports
**Section:** other | **Similarity:** 0.559

hy: A cohort study. Am. J. Kidney Dis. 76, 90¬ñ99 (2020). 21. Wu, Y. et al. e association of hematuria on kidney clinicopathologic features and renal outcome in patients with diabetic nephropathy: A biopsy-based study. J. Endocrinol. Investig. 43, 1213¬ñ1220 (2020). 22. Imran, S., Eva, G., Christopher, S., Flynn, E. & Henner, D. Is specic gravity a good estimate of urine osmolality? J. Clin. Lab. Anal. 24, 426¬ñ430 (2010). 23. Sawka, M. N. et al. American College of Sports Medicine position stand. Exercise and uid replacement. Med. Sci. Sports Exerc. 39, 377¬ñ390 (2007). 24. Sharp, V. J., Barnes, K. T. & Erickson, B. A. Assessment of asymptomatic microscopic hematuria in adults. Am. Fam. Phys. 88, 747¬ñ754 (2013). 25. Grossfeld, G. D. et al. Evaluation of asymptomatic microscopic hematuria in adults: e American Urological Association best practice policy¬óPart I: Denition, detection, prevalence, and etiology. Urology 57, 599¬ñ603 (2001). 26. Yuste, C. et al.

---

### Chunk 17/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.557

ngofnausea,genital
infection,dehydration,andabdominalpain.InanRCT,
therewerenoepisodesofdiabeticketoacidosisandsimilarnumbersofhypoglycemiabetweenplaceboanddapagliozin,mostlyoccurringinthoseoninsulin.529ThereislimitedresearchonkidneyeffectsofSGLT2iinchildren.Onestudyof8childrenwithCKDandproteinuria
foundareductionin24-hoururineproteinfromameanof2.1
g/dtoameanof1.5g/dover12weeks.530Theoretically,theglycosuriceffectofSGLT2imayleadtoanegativecalorie
balance,interferingwithoptimalgrowth,especiallyinsmall
childrenwithunderlyinggrowthretardation.Clinicaltrialsin
thepediatricpopulationaresuggested,includinginthose
withspecicetiologiesandatdifferentagegroups(i.e.,prepubescent,peripubescent,andpostpubescent).3.8Mineralocorticoidreceptorantagonists(MRA)TheWorkGrouphighlightsakeyrecommendationandpractice
pointsfromtheKDIGO2022ClinicalPracticeGuidelineforDiabetesManagementinChronicKidneyDisease.23
‚Äì1‚Äì0.500.511.52Mean annual rate of change in estimated GFR (ml/min per 1.73 m2 per year)Empagli

---

### Chunk 18/30
**Article:** Automated urine sediment analyzers underestimate the severity of hematuria in glomerular diseases (2021)
**Journal:** Scientific Reports
**Section:** discussion | **Similarity:** 0.556

pH of the urine was categorized as follows; 5, 6, 6.5, 7, 8 and 9.e Urisys 2400 and Cobas u 601 urine analyzers both contain a built-in refractometer, and the specic gravity (SG) was measured via refractometry. e scale of urine SG ranged from 1.000 to 1.050. In dilute urine, the RBCs absorb water, swell, and may rupture. In concentrated urine, the RBCs tend to shrink and become crenated. A urine SG of 1.010 corresponds to approximately 300mOsm/kg, similar to the osmolarity of  plasma22, and a urine SG > 1.020 oen indicates  dehydration23. In this study, therefore, urine samples with SG < 1.010 and > 1.020 were considered dilute and concentrated urine, respectively.Statistical analysis. e data are expressed as the median (interquartile range). e values obtained for the two groups were compared using the Mann‚ÄìWhitney U test.

---

### Chunk 19/30
**Article:** Bases Metab√≥licas das Doen√ßas Cr√¥nicas e Gerenciamento - Glica√ß√£o 2 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.552

gn√≥stico: Nenhuma no momento.
## Plano:
- Prescri√ß√£o:
  - Inserir mais aqui
  - Metformina (Glifage XR) 1 g no jantar; considerar 500‚Äì850 mg na primeira refei√ß√£o conforme resist√™ncia insul√≠nica/IMC; ajustar dose total preferencialmente ‚â§1.600‚Äì1.700 mg/dia; avaliar fun√ß√£o renal antes e durante o uso.
  - Considerar suplementos antioxidantes e moduladores do metabolismo conforme avalia√ß√£o individual (n√£o especificados).
- Pr√≥ximos Passos/Exames:
  - Hemoglobina glicada para monitoriza√ß√£o de glica√ß√£o.
  - Insulina de jejum; meta ideal ‚â§6 ¬µU/mL.
  - Curva insulin√™mica-glic√™mica para caracterizar resist√™ncia insul√≠nica.
  - Perfil lip√≠dico, incluindo triglicer√≠deos e, quando poss√≠vel, LDL oxidada.
  - Revis√£o detalhada da dieta para reduzir carga glic√™mica e ajustar qualidade dos carboidratos.
  - Fun√ß√£o renal antes de iniciar/ajustar metformina.

---

### Chunk 20/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.552

S,CarlinJB,etal.Albuminuria:populationepidemiology
andconcordanceinAustralianchildrenaged11‚Äì12yearsandtheirparents.BMJOpen.2019;9:75‚Äì84.308.RademacherER,SinaikoAR.Albuminuriainchildren.CurrOpinNephrolHypertens.2009;18:246‚Äì251.309.TsiousC,MazarakiA,DimitriadisK,etal.Microalbuminuriainthepaediatricage:currentknowledgeandemergingquestions.ActaPaediatr.2011;100:1180‚Äì1184.310.EmmaF,GoldsteinS,BaggaA,etal.PediatricNephrology.8thed.Springer;2022.311.BrinkmanJW,deZeeuwD,DukerJJ,etal.Falselylowurinaryalbuminconcentrationsafterprolongedfrozenstorageofurinesamples.ClinChem.2005;51:2181‚Äì2183.312.SacksDB,ArnoldM,BakrisGL,etal.Executivesummary:guidelinesand
recommendationsforlaboratoryanalysisinthediagnosisandmanagementofdiabetesmellitus.ClinChem.2011;57:793‚Äì798.313.SeegmillerJC,MillerWG,BachmannLM.Movingtowardstandardizationofurinealbuminmeasurements.EJIFCC.2017;28:258‚Äì267.314.NationalInstituteofStandardsandTechnology.CerticationofStandardReferenceMaterial2925RecombinantHumanSerumA

---

### Chunk 21/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.550

diabetes): 0 RCTs‚Ä¢ Uric acid: 30 studies (32 reports)‚Ä¢ Aspirin: 5 RCTs‚Ä¢ Angiography: 5 RCTs (7 reports)‚Ä¢ NOAC: 7 RCTs (13 reports)Included nonrandomized studies:‚Ä¢ Biopsy: 65 studies*‚Ä¢ eGFR: 47 studies (48 reports)‚Ä¢ ACR_PCR: 0 studies‚Ä¢ POC creatinine: 55 studies‚Ä¢ POC dipstick: 65 studies (66 reports)Included studies:RCTs: 145 (368 reports)Non-randomized: 232 studies (234 reports)* 38 studies included in the analysesNonrandomized studies (cross-sectional, pre-post, prospective observational, noncomparative):‚Ä¢ PubMed: 4944‚Ä¢ Embase: 5196‚Ä¢ CINAHL: 146‚Ä¢ Central: 82‚Ä¢ Other reviews: 68‚Ä¢ Handsearching: 74Randomized controlled trials identied from databases:‚Ä¢ PubMed: 7030‚Ä¢ Embase: 5716‚Ä¢ Cochrane Central: 6999‚Ä¢ KDIGO Diabetes 2022 GL: 393‚Ä¢ Other reviews: 153‚Ä¢ Handsearching: 60
Figure57|Searchyieldandstudyowdiagram.ACR,albumin-to-creatinineratio;CINALL,CumulativeIndextoNursingandAlliedHealthLiterature;eGFR,estimatedglomerularltrationrate;GLP-1,glucagon-

---

### Chunk 22/30
**Article:** Fisiologia e Bioqu√≠mica do Sistema Imune II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.550

tegrativas ~5,3‚Äì5,2; diagn√≥stico ‚â•6,5; risco alto ‚â•5,6. Evolu√ß√µes podem levar 2‚Äì3 anos.
- Frutosamina: ~20 dias; complementar.
- HGI: diferen√ßa entre HbA1c observada e predita da glicemia; estratos de risco orientam acompanhamento trimestral.
- MDA: <4,8; GPx: >400 (ideal 800‚Äì1000); antioxidantes totais: 560‚Äì1120.
- TAIG: TG/(glicose/2); meta <8; TG/HDL: mulheres <1,4; homens <1,2.
- Lipidograma/SREBP1c/2: excesso de saturadas + a√ß√∫car eleva SREBP1c, VLDL e LDL ox; aumenta hepcidina e altera ferro.
- Ferro/ferritina/transferrina: satura√ß√£o 20‚Äì50% (evitar <20%); hiperferritinemia inflamat√≥ria (‚ÄúSerum Ferritin Lacking Iron‚Äù).
- TNF-Œ±: meta <8,1; IL-6: meta <3,4; rela√ß√£o direta em obesidade inflamada.
- HOMA-Œ≤: 167‚Äì175; HOMA-IR: <2,15; glicemia alvo 60‚Äì90; insulina ideal ~6‚Äì7 (at√© 8 em inflama√ß√£o).
- Homociste√≠na: <7,9; correlaciona com PCR; polimorfismos FUT/MTHFR podem elev√°-la.

---

### Chunk 23/30
**Article:** Carboidratos IV (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.548

cose, evidenciando resist√™ncia perif√©rica √† insulina.
- A an√°lise isolada da glicemia de jejum pode levar a um diagn√≥stico incorreto de "sobrepeso saud√°vel", mascarando um problema metab√≥lico grave.
> **Sugest√µes da IA**
> O uso deste estudo de caso foi fundamental para traduzir a teoria em pr√°tica. Voc√™ demonstrou de forma excelente por que a glicemia de jejum isolada √© insuficiente. Ao apresentar os dados da curva, seria √∫til destacar verbalmente os valores de pico da insulina e da glicose e compar√°-los com os valores de refer√™ncia ideais, para que os alunos compreendam imediatamente a magnitude do problema. A sua cr√≠tica √† miopia do diagn√≥stico de "gordinho saud√°vel" foi muito pertinente e memor√°vel.
### 8. Estudo de Caso 2: Paciente Feminina com M√∫ltiplas Comorbidades e Hipoglicemia de Rebote
- Paciente: 71 anos, 1,54m, 87 kg, com m√∫ltiplas queixas (dores, alergias, depress√£o, hipertens√£o, etc.) e polifarm√°cia (incluindo estatina e Saxenda).

---

### Chunk 24/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.548

Ô¨Çuid restriction plus furosemide plus salt intake 6.3 ¬± 8.7mmol/L; P = 0.7). Additionally, the furosemide group experienced an increased frequency of hypokalemia (serum  [K+]  3.0mmol/L; P = 0.01) [30]. Furthermore, a trend toward an increased frequency of acute kidney injury was observed in the furosemide group and among patients Ô¨Çuid-restricted to 800mL/d without statistical diÔ¨Äerence.Sodium-glucose cotransporter (SGLT) 2 inhibitors have been approved as oral medications for type 2 diabetes, and more recently for treatment of chronic heart failure and advanced chronic kidney disease. They inhibit SGLT2 in the renal proximal tubules and increase glucose excretion into the urine, resulting in a solute (osmotic) diuresis and a secondary increase in free water excretion.

---

### Chunk 25/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** introduction | **Similarity:** 0.546

roteinuriadoesnotallowcharacterizationofthesource.If
urinePCRisused,urineACRshouldalsobemeasuredto
chapter1www.kidney-international.orgS192KidneyInternational(2024)105(Suppl4S),S117‚ÄìS314

bettercharacterizeproteinuria.Signicantalbuminuriagenerallyreectsglomerulardamage.304Importantly,inthecontextofscreeningforchildrenwithdiabetes,ACRremainsthestandard,inlinewithadultguidelines.Thesameconsiderationsofusingrstmorningsamples(becauseoforthostaticproteinuria)andconsideringtran-
sientlyincreasedproteinuriaduringintercurrentillnessor
afterexerciseapplytochildrenaswellasadults.Orthostatic
proteinuriaisestimatedtoaffect2%‚Äì5%ofadolescents.305Ageandbodysizeareimportantforinterpretingproteinuriaandalbuminuria.Intermandpretermneonates,PCRishigh
(PCR1000‚Äì3000mg/g[100‚Äì300mg/mmol])intherstdaysandweeksoflife,andisrelatedtoglomerularandtubularlosses
ofproteinfromimmaturenephrons,aswellasverylowcreati-
ninefromlowmusclemass.Recentstudiesoutlineproteinuria
rangesforneonates,includingforpreterm

---

### Chunk 26/30
**Article:** Bases Metab√≥licas das Doen√ßas Cr√¥nicas e Gerenciamento - Glica√ß√£o 2 (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.546

e jejum ideal ‚â§6 ¬µU/mL; aceit√°vel at√© 10 ¬µU/mL. Paciente refere 4‚Äì5 ¬µU/mL.
  - Hemoglobina glicada: melhor indicador de glica√ß√£o do que glicemia de jejum; pode estar elevada mesmo com glicemia normal (compat√≠vel com picos glic√™micos e alta carga glic√™mica).
  - Glicemia de jejum isolada √© exame ‚Äúpobre‚Äù para avaliar glica√ß√£o.
  - Recomendada curva insulin√™mica-glic√™mica para avaliar resist√™ncia insul√≠nica e resposta a carboidratos.
- Gen√©tica:
  - Polimorfismos em FTO (5 variantes), MC4R (m√∫ltiplas), PPAR-Œ≥, TCF7L2, SOD, CETP, BDNF, CCK, LEP e LEP-R associados a resist√™ncia insul√≠nica, obesidade, menor saciedade, risco de diabetes e transporte lip√≠dico desfavor√°vel.
- Sinais e correla√ß√µes fisiopatol√≥gicas:
  - Intera√ß√£o AGE-RAGE ativa NF-Œ∫B, aumenta citocinas e ROS, perpetuando inflama√ß√£o cr√¥nica.
  - Excesso de ultraprocessados e preparos em alta temperatura eleva produtos de glica√ß√£o avan√ßada (AGEs).

---

### Chunk 27/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.545

stClin.2006;58:190‚Äì197.328.CroalBL,MutchWJ,ClarkBM,etal.Theclinicalapplicationofaurine
albumin:creatinineratiopoint-of-caredevice.ClinChimActa.2001;307:15‚Äì21.329.CurrinSD,GondweMS,MayindiNB,etal.Diagnosticaccuracyof
semiquantitativepointofcareurinealbumintocreatinineratioandurinedipstickanalysisinaprimarycareresourcelimitedsettingin
SouthAfrica.BMCNephrol.2021;22:103.330.DajakM,BonticA,UgnjatovicS,etal.[Evaluationofmethodsforrapidmicroalbuminuriascreeninginkidneydiseasedpatients].SrpArhCelokLek.2012;140:173‚Äì178[inSerbian].331.DavidsonMB,BazarganM,BakrisG,etal.ImmunoDip:animproved
screeningmethodformicroalbuminuria.AmJNephrol.2004;24:284‚Äì288.332.DavidsonMB,SmileyJF.Relationshipbetweendipstickpositiveproteinuriaandalbumin:creatinineratios.JDiabetesComplications.1999;13:52‚Äì55.333.deGrauwWJ,vandeLisdonkEH,vandeHoogenHJ,etal.Screeningfor
microalbuminuriaintype2diabeticpatients:theevaluationofadipsticktestingeneralpractice.DiabetMed.1995;12:657‚Äì663.334.Fern√°ndezFern√°ndezI,P√°

---

### Chunk 28/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XI (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.544

ndem a insulina <6.
- Sugerido passo‚Äëa‚Äëpasso: se insulina ‚â•10 ŒºU/mL em jejum + sintomas cognitivos ‚Üí considerar curva glic√™mica/insulin√™mica; avaliar confounders (medica√ß√µes, sono, estresse) e repetir exame.
### 4. Curva glic√™mica/insulin√™mica e din√¢mica p√≥s‚Äëprandial
- Justificativa: queixas situacionais e padr√£o alimentar rico em carboidratos simples, mesmo em n√£o obesos.
- HbA1c √© √∫til, mas lenta; curva mostra resposta aguda.
- Exemplo 75 g glicose: 30‚Äô 130 mg/dL; 60‚Äô 169; 90‚Äô 151; 120‚Äô 161 mg/dL ‚Üí resposta sustentada e elevada; ideal √© retorno <140 mg/dL em ~2 h.
- Crit√©rios pr√°ticos de preocupa√ß√£o: pico >160 mg/dL aos 60‚Äô e >140 mg/dL aos 120‚Äô; pr√≥ximos passos: interven√ß√£o diet√©tica, atividade f√≠sica, reavalia√ß√£o.
- V√≠nculo com refei√ß√µes reais: p√£o branco + geleia + suco ‚Üí pico maior; prote√≠na + fibra ‚Üí pico menor.
### 5.

---

### Chunk 29/30
**Article:** Dieta Cetog√™nica - Parte I (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.543

 nica jejum < 5 ¬µU/mL; cetoacidose ~0.
  - Cetonas: cetog√™nica ‚â• 0,5 at√© 7‚Äì8 (jejum prolongado); cetoacidose > 10, frequentemente 20‚Äì25.
  - pH: cetog√™nica ~7,4; cetoacidose < 7,3 (acidose).
- Medi√ß√£o:
  - Glicos√≠metros com tiras de cetonas; zona √≥tima at√© ~3. Jejuns prolongados elevam cetonemia.
### 10. Cetoadapta√ß√£o e ‚Äúketo flu‚Äù
- Mecanismo e sintomas:
  - Mobiliza√ß√£o de glicog√™nio (~500 g) ‚Üí perda de √°gua (~1 kg) e eletr√≥litos; sintomas: cefaleia, tontura, c√¢imbras, constipa√ß√£o/diarreia, ins√¥nia, irritabilidade.
- Preven√ß√£o e manejo:
  - Progress√£o gradual (comida de verdade ‚Üí low-carb ‚Üí cetog√™nica, salvo indica√ß√£o cl√≠nica).
  - Hidrata√ß√£o ‚â• 2 L/d; eletr√≥litos (sal, pot√°ssio, magn√©sio; sal light; produtos comerciais).
  - Aten√ß√£o a hipertensos e polifarm√°cia: monitorar PA, ajustar diur√©ticos/anti-hipertensivos.
### 11.

---

### Chunk 30/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.543

22:369.318.McTaggartMP,NewallRG,HirstJA,etal.Diagnosticaccuracyofpoint-of-
caretestsfordetectingalbuminuria:asystematicreviewandmeta-analysis.AnnInternMed.2014;160:550‚Äì557.319.AbitbolC,ZillerueloG,FreundlichM,etal.Quantitationofproteinuriawithurinaryprotein/creatinineratiosandrandomtestingwithdipsticksinnephroticchildren.JPediatr.1990;116:243‚Äì247.320.AgardhCD.Anewsemiquantitativerapidtestforscreeningformicroalbuminuria.PracticalDiabetes.1993;10:146‚Äì147.321.AgarwalR,PanesarA,LewisRR.Dipstickproteinuria:canitguide
hypertensionmanagement?AmJKidneyDis.2002;39:1190‚Äì1195.322.AroraS,LongT,MenchineM.Testcharacteristicsofurinedipstickfor
identifyingrenalinsufciencyinpatientswithdiabetes.WestJEmergMed.2011;12:250‚Äì253.323.ChangCC,SuMJ,HoJL,etal.Theefcacyofsemi-quantitativeurineprotein-to-creatinine(P/C)ratioforthedetectionofsignicantproteinuriainurinespecimensinhealthscreeningsettings.Springerplus.2016;5:1791.324.ChoMC,JiM,KimSY,etal.EvaluationoftheURiSCANsupercassetteACRsemiquantita

---

